Constraints on hospitalists and surgeons and restricted orthopedic admission criteria can exacerbate patients’ distress that comes from clinicians’ disagreements.
AMA J Ethics. 2023;25(12):E873-877. doi:
10.1001/amajethics.2023.873.
Bias toward allopathic medicine in the research funding and publication of study results makes it difficult for physicians and others to find accurate data about the efficacy of non-Western, nonallopathic treatments.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
The drug Neurontin is used as an example of why it is permissible for physicians to engage in off-label prescribing, but off-label marketing by pharmaceutical companies is prohibited by the FDA.